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Background 
 
Although considerable progress has been made in treating cancer over the past decade 
with a gradual decline in cancer death rates, there are still over 8 million deaths 
annually from cancer worldwide.  Cures of solid tumors can often be achieved by 
locally directed therapies such as surgery or radiotherapy, but eradication of metastatic 
cancer, where treatment relies principally on chemotherapy, is rarely successful.  Despite 
considerable advances in drug discovery, resistance to chemotherapy confounds the 
effective treatment of patients. Cancer cells can become resistant to a single drug or they 
may acquire broad cross-resistance to mechanistically and structurally unrelated drugs 
(multidrug resistance (MDR)). ATP-binding cassette (ABC) proteins, present in most 
living organisms from prokaryotes to mammals, include the best known mediators of 
MDR.  In particular, MDR pump ABCB1 (MDR1-Pgp) actively extrudes many types of 
drugs from cancer cells, thereby conferring resistance to those agents [1].  
 
I. Accomplishment of research objectives  
 
The major objective of this particular application was to further characterize compounds 
that I identified to be candidate ABC transporter “sensitizers” [2]. The basic hypothesis 
was that the pharmacogenomic approach I implemented can be exploited to discover 
“MDR-inverse” compounds that selectively target multidrug resistant cancer cells. 
It was additionally hypothesized that bioinformatic and biochemical analyses would help 
to elucidate the mechanism of action as well as the structural determinants of such 
compounds. The results are presented according to the milestones suggested in the 
original proposal. 
 
Milestone 1: (1) Compounds of interest are identified in DTP's dataset; 50-100 
compounds are tested in cytotoxicity experiments; (2) delineating chemical features are 
defined.  
 
1. Identification of MDR1-inverse compounds 
Analysis of an initial subset of the database restricted to 1,429 compounds demonstrated 
strong correlation, measured by Pearson's correlation coefficient (PCC), between drug 
sensitivity and Pgp expression across the NCI60 cell panel. A positively correlated 
thiosemicarbazone derivative (NSC73306) was identified and confirmed to exhibit 
increased cytotoxicity in Pgp expressing cells [2]. In an effort to screen for compounds 
that behaved similarly, the correlation analysis was extended to include a larger 
dataset of approximately 42,000 compounds and a subset containing more reliable 
correlation data of 17,000 compounds. Twenty two compounds from the 17K dataset 
were first selected by Pearson's correlation coefficient (PCC>=0.4) and by availability 
from DTP's repository for in vitro screening. Six compounds were found to preferentially 
inhibit Pgp overexpressing cells in at least three of the five cell line models. Identification 
of structural analogs among the six compounds prompted the attempt to utilize the 42K 
correlation dataset by complementing the correlation data of candidate compounds with 
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their chemical structure data. Calculation of statistical significance of correlation by 
bootstrapping and evaluation of Tanimoto's structural similarity allowed the inclusion of 
additional candidate compounds below the 0.4 PCC threshold. The extended screenings 
revealed a group of 37 compounds (“Discovery-set”) demonstrating various levels of 
growth inhibition against Pgp expressing cells (submitted). 
 
 
2. QSAR 
 
Analysis of the DTP dataset 
Chemical clustering of the Discovery-set defined two coherent sets. To identify common 
features that may be responsible for MDR-inverse activity, we generated three-
dimensional pharmacophore models for each cluster using the most active compounds 
as templates. QSAR analysis identified descriptors that predict MDR1 inverse activity 
with very high accuracy (r2=0.92) (submitted).  
 
 
Figure 1. Dendrogram showing the average-linkage hierarchical clustering of the 37 
confirmed MDR1-invese compounds. The distance matrix is derived from Tanimoto 
similarity indices. Numbers represent NSC codes. The two major clusters are colored 
green (“TSC-cluster”) and yellow (“10580-cluster”). Pharmacophore models derived 
from the two sets are shown. (Taken from the submitted manuscript)  
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Analysis of focused libraries 
Additional work aimed at the delineation of structural features responsible for the MDR1-
inverse activity of NSC 73306. A range of analogs were synthesized and tested to 
determine the structural features required for the MDR1-inverse activity of this 
thiosemicarbazone (ITS). A number of analogs demonstrated improved MDR1-inverse 
activity over the lead isatin-β-thiosemicarbazone, NSC73306. The MDR1-inverse 
pharmacophore highlights the importance of aromatic/hydrophobic features at the N4 
position of the thiosemicarbazone, and the reliance on the isatin moiety as key 
bioisosteric contributors for MDR1 selectivity. Additionally, a quantitative structure-
activity relationship (QSAR) model that yielded a cross-validated correlation coefficient 
of 0.85 effectively predicts the cytotoxicty of untested thiosemicarbazones. Together, the 
pharmacophore and QSAR models serve as effective approaches for predicting structures 
with MDR1-inverse activity, and aid in directing the search for the mechanism of action 
of NSC73306 and its congeners [3]. 
 
 
Figure 2. Pharmacophore model derived from the focused ITS library [3]. 
 
 
Milestone 2: Interaction with Pgp 
 
To assess whether the potentiation of cytotoxicity against Pgp-expressing cells is robust, 
and not cell-line specific, compounds that were available in larger quantities were tested 
on further multidrug resistant cell lines. Irrespective of the selection drug maintaining 
Pgp expression, the tissue of origin, and in a genetically engineered (transfected) cell line 
(NIH 3T3 G185), all compounds showed elevated toxicity in Pgp-expressing cells 
relative to their parental line, demonstrating that the observed potentiation of cytotoxicity 
is not restricted to KB-V1 cells and functional Pgp is the main determinant for 
selective activity. In addition, we have found that (i) resistance to NSC 73306 is 
accompanied by reduced Pgp expression (The analysis of the transcriptional profile 
associated to resistance against MDR1-inverse compounds is underway); (ii) there is no 
direct interaction between Pgp and NSC 73306 [4]; (iii) NSC73306 is not more toxic to 
cells that overexpress other ABC transporters than Pgp (manuscript in preparation). 
Interestingly, (iv) NSC73306 is a transport substrate for ABCG2 and can effectively 
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inhibit ABCG2-mediated drug transport and reverse resistance to both mitoxantrone and 
topotecan in ABCG2-expressing cells (manuscript in preparation).   
Overall, NSC73306 seems to be a potent modulator of ABCG2 that does not interact with 
MRP1, MRP4, or MRP5. Collectively, these data suggest that NSC73306 may be used, 
due to its dual mode of action, as an effective agent to overcome drug resistance by 
eliminating P-glycoprotein-overexpressing tumor stem cells [5] and by acting as a potent 
modulator that resensitizes ABCG2-expressing cancer cells to chemotherapeutics 
(manuscript in preparation).  
 
Milestone 3: Mechanism of action, preclinical studies 
 
Understanding the mechanism of action behind Pgp-potentiated toxicity would be a 
major breakthrough and would establish the conditions for a mechanism-based drug 
discovery research and the development of a molecular target-based research strategy. 
Although we have gained a deeper insight into the plausible mechanism of action of at 
least a subset of the MDR-inverse compounds, the underlying physiological principles 
remain obscure.  
 
 
Self-organizing maps (SOM) provide a visually compelling clustering algorithm to 
analyze the relation of drug activity patterns to functional categories representing distinct 
modes of action. To find out if the MDR1-inverse compounds are associated with a 
specific response category, we projected the Discovery-set on the SOM representing 
cytotoxicity measurements of the DTP tumor cell screen (http://spheroid.ncifcrf.gov). 
Strikingly, most of the active MDR1-inverse compounds project to the S-region (linked 
to nucleic acid metabolism), together with metal chelation complexes and chelators. 
Typically, metal complexes projecting to the S region show some degree of similarities in 
both structure and cytotoxic response profiles. To explore the role of chelation and metal 
ions in the activity of MDR1-inverse compounds, experiments were performed with free 
ligands and chelated complexes. We found that the MDR1-inverse agents possess 
cytotoxic response profiles similar to their metal chelates, and that the metal type does 
not appear to significantly affect the activity of these metal chelates, indicating that either 
they are prodrugs and the active species are their metal chelates formed in situ, or the 
metal chelates serve as carriers for chelators which themselves are the active drug 
molecules (submitted). 
 
Drug Development: preclinical studies  
 
In the framework of DTP’s Drug Development Program (National Cancer Institute, 
NIH), a study is underway to evaluate the in vivo anticancer effects of NSC73306. The 
overall aim of this collaboration is to facilitate preclinical development of NSC 73306. 
The first task was to develop and validate a sensitive analytical method to quantify the 
presence of NSC73306 in biological fluids (initially for mouse and human plasma). We 
characterized the in vitro stability of NSC 73306 in aqueous buffers, plasma and 
appropriate sample handling and storage procedures. We determined the extent of protein 
binding, optimized solubility, drug formulation, dosing schedules, and pharmacokinetics. 
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In all, we have identified a bioavailable formulation that shows antitumor potential in 
hollow-fiber models [6]. Preliminary lethality/toxicity studies and evaluation of drug 
efficacy in mice and dogs are underway. 
 
In summary, the goals of the proposal were met: (i) The chemogenomic approach was 
successfully employed to identify several anticancer drug candidates with enhanced 
toxicity in otherwise multidrug resistant (MDR) cells (Discovery-set). (ii) Analysis of the 
Discovery-set in relation to the DTP drug database led to the formulation of initial QSAR 
and pharmacophore analyses. (iii) Biochemical data coupled with the unsupervised self-
organizing map-based clustering of the MDR1-inverse compounds suggested a 
mechanism of action linked to metal chelation; (iv) preclinical studies evaluating the in 
vivo effect of NSC 73306 have been initiated.  
 
During the granting period, several papers directly relating to the proposed aims have 
been published [3-5].  
 
The manuscript summarizing our results obtained with the Discovery-set is currently 
under review (Dora Turk, Matthew D. Hall, Benjamin F. Chu, Joseph A. Ludwig, Henry 
M. Fales, Michael M. Gottesman, Gergely Szakács: Identification of compounds 
selectively killing multidrug resistant cancer cell). The results have been presented at a 
recent national meeting (Türk Dóra, Matthew D. Hall, Michael M. Gottesman, Szakács 
Gergely: MDR1-INVERZ CITOTOXIKUS HATÁST MUTATÓ VEGYÜLETEK 
VIZSGÁLATA, poszter, 39. Membrán-transzport konferencia, 2009). 
 
In addition, I have coauthored several original papers [7, 8] and review articles relating to 
the problem of ABC transporters and multidrug resistance [9-12]. 
 
II. New objectives established during the course of work and new lines of research. 
 
During the course of the three years of this project, we followed the initial research 
strategy. The new objectives logically follow the line of drug development. Since we 
now understand that the initial discovery of a single MDR-inverse agent was only the 
“tip of the iceberg” [2], our next aim is to aid the preclinical development of the best 
drug candidates. The relevance of this project to applied research is evident, given the 
unmet need of conquering multidrug resistant cancer. Based on the promising results 
obtained in this project, a consortium was formed by academic researchers, renowned 
experts of drug discovery research and biotech companies working in the field of 
transporter research. The aim is to target industrial research funds in order to establish the 
framework for the preclinical development of the most promising MDR-inverse molecules, 
setting the stage for a fresh therapeutic approach that may eventually translate into 
improved patient care.  
 
III.  Training  
 
The training objective of the OTKA Postdoctoral Fellowship was to ease my 
reintegration to Hungary. While the difficulties I met were unexpected and sometimes 
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insurmountable, I wouldn’t have been able to get established without the valuable 
contribution of this grant mechanism. During these three years, I published 12 papers with 
a cumulative impact factor of 85, and I transitioned from a postdoctoral fellow to a group 
leader in the Institute of Enzymology. Based on the results presented in this report, I was 
able to attract further national and international funding, as well as talented students and 
postdoctoral fellows.  
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